The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Roytberg G.E.

JSC «Meditsina», Moscow, Russia

Usychkin S.V.

JSC «Meditsina», Moscow, Russia

Bojko A.V.

GBOU VPO «Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet» Minzdrava Rossii, Tomsk

Methodological aspects of extreme hypofractionated external beam radiotherapy for prostate cancer with target volume immobilization by an endorectal balloon

Authors:

Roytberg G.E., Usychkin S.V., Bojko A.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2016;5(6): 47‑53

DOI: 10.17116/onkolog20165647-53

Read: 1491 times

Download PDF (RU)
Contact the author
Table of contents

METHODOLOGICAL ASPECTS OF EXTREME HYPOFRACTIONATED EXTERNAL BEAM RADIOTHERAPY FOR PROSTATE CANCER WITH TARGET VOLUME IMMOBILIZATION BY AN ENDORECTAL BALLOON
METHODOLOGICAL ASPECTS OF EXTREME HYPOFRACTIONATED EXTERNAL BEAM RADIOTHERAPY FOR PROSTATE CANCER WITH TARGET VOLUME IMMOBILIZATION BY AN ENDORECTAL BALLOON

To cite this article:

Roytberg GE, Usychkin SV, Bojko AV. Methodological aspects of extreme hypofractionated external beam radiotherapy for prostate cancer with target volume immobilization by an endorectal balloon. P.A. Herzen Journal of Oncology. 2016;5(6):47‑53. (In Russ.)
https://doi.org/10.17116/onkolog20165647-53

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Remote resu­lts of treatment of patients with prostate cancer who unde­rwent radiation therapy in a combined version. P.A. Herzen Journal of Onco­logy. 2025;(3):14-19
Global coagulation tests in pharmacological prophylaxis of venous thro­mboembolism in patients with prostate cancer after radi­cal prostatectomy. P.A. Herzen Journal of Onco­logy. 2025;(5):41-46
Epidemiology and prevention of prostate cancer. Russian Journal of Preventive Medi­cine. 2025;(7):111-118
Cost-effectiveness analysis of triptorelin therapy for patients with prostate cancer in state healthcare system of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):83-92
Using the PathVision.ai model of medi­cal deci­sion support in morphological diagnostics of prostate cancer in biopsy mate­rial. Russian Journal of Archive of Pathology. 2025;(6):34-41
Abstract:

Objective — to study the methodological features of the efficiency of target volume immobilization with an endorectal balloon during extremely hypofractionated image-guided radiotherapy (IGRT) for prostate cancer. Material and methods. Fifteen patients with localized prostate cancer were treated with an extremely hypofractionated IGRT using 40 Gy in 5 sessions of daily radiation in a single focal dose (SFD) of 8 Gy. A special transrectal Pro-Tekt balloon was used to immobilize the prostate during CT/MR-simulation and treatment sessions. Image-guidance and correction of the target position during treatment (IGRT) were done by cone beam computed tomography on the linear accelerator (CBCT) table and by four prostate-implanted radiopaque marks visible on orthogonal kV image pairs. The fiducial displacement relative to their reference position during a radiation therapy session was retrospectively analysed. The findings were used to calculate CTV-PTV margins. Results. The mean fiducial displacement for ERB-immobilized prostate between images acquired during treatment session varied from 0.1±0.4 to 0.59±0.51 mm. The fiducials displacement in 100, 97, and 99% of measurements was less than 2.0 mm for vertical, cranio-caudal and lateral directions respectively. CTV-PTV margins calculated from the intrafractional prostate displacements were from 1.27 to 1.89 mm. Conclusion. Endorectal balloon is an effective method for prostate immobilization during extremely hypofractionated IGRT for prostate cancer. Target immobilization and short dose delivery time can reduce CTV-PTV margins to 2 mm.

Keywords:

extreme hypofractionated external-beam radiotherapy
prostate cancer
immobilization
endorectal balloon

Authors:

Roytberg G.E.

JSC «Meditsina», Moscow, Russia

Usychkin S.V.

JSC «Meditsina», Moscow, Russia

Bojko A.V.

GBOU VPO «Sibirskiĭ gosudarstvennyĭ meditsinskiĭ universitet» Minzdrava Rossii, Tomsk

Close metadata

References:

  1. Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA et al. Prostate cancer, version 1.2016. J Natl Compr Canc Netw. 2016;14(1):19-30.
  2. King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC Jr. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009;73(4):1043-1048. doi:10.1016/j.ijrobp.2008.05.059
  3. King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(2):877-882. doi:10.1016/j.ijrobp.2010.11.054
  4. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013;109(2):217-221. doi:10.1016/j.radonc.2013.08.030
  5. Katz AJ, Santoro M, Diblasio F, Ashley R. Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years. Radiat Oncol. 2013;8:118. doi:10.1186/1748-717X-8-118
  6. Katz AJ, Kang J. Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol. 2014;4:240. doi:10.3389/fonc.2014.00240
  7. Davis J, Sharma S, Shumway R, Perry D, Bydder S, Simpson CK, D'Ambrosio D. Stereotactic body radiotherapy for clinically localized prostate cancer: toxicity and biochemical disease-free outcomes from a multi-institutional patient registry. Cureus. 2015;7(12):e395. doi:10.7759/cureus.395
  8. Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(3):686-692. doi:10.1016/j.ijrobp.2012.05.023
  9. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys. 2007;68(5):1424-1430. doi:10.1016/j.ijrobp.2007.01.067
  10. Boike TP, Lotan Y, Cho LC, Brindle J, DeRose P, Xie XJ et al. Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J Clin Oncol. 2011;29(15):2020-2026. doi:10.1200/JCO.2010.31.4377
  11. Hannan R, Tumati V, Xie XJ, Cho LC, Kavanagh BD, Brindle J et al. Stereotactic body radiation therapy for low and intermediate risk prostate cancer-results from a multi-institutional clinical trial. Eur J Cancer. 2016;59:142-151. doi:10.1016/j.ejca.2016.02.014
  12. Kim DW, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D et al. Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2014;89(3):509-517. doi:10.1016/j.ijrobp.2014.03.012
  13. van Herk M. Errors and margins in radiotherapy. Semin Radiat Oncol. 2004;14(1):52-64. doi:10.1053/j.semradonc.2003.10.003
  14. Willoughby TR, Kupelian PA, Pouliot J, Shinohara K, Aubin M, Roach M 3rd et al. Target localization and real-time tracking using the Calypso 4D localization system in patients with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2006;65(2):528-534. doi:10.1016/j.ijrobp.2006.01.050
  15. Kupelian P, Willoughby T, Mahadevan A, Djemil T, Weinstein G, Jani S et al. Multi-institutional clinical experience with the Calypso System in localization and continuous, real-time monitoring of the prostate gland during external radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67(4):1088-1098. doi:10.1016/j.ijrobp.2006.10.026
  16. Langen KM, Willoughby TR, Meeks SL, Santhanam A, Cunningham A, Levine L, Kupelian PA. Observations on real-time prostate gland motion using electromagnetic tracking. Int J Radiat Oncol Biol Phys. 2008;71(4):1084-1090. doi:10.1016/j.ijrobp.2007.11.054
  17. Kupelian PA, Langen KM, Willoughby TR, Zeidan OA, Meeks SL. Image-guided radiotherapy for localized prostate cancer: treating a moving target. Semin Radiat Oncol. 2008;18(1):58-66. doi:10.1016/j.semradonc.2007.09.008
  18. Litzenberg DW, Balter JM, Hadley SW, Hamstra DA, Willoughby TR, Kupelian PA et al. Prostate intrafraction translation margins for real-time monitoring and correction strategies. Prostate Cancer. 2012;2012:130579. doi:10.1155/2012/130579
  19. Smeenk RJ, Teh BS, Butler EB, van Lin EN, Kaanders JH. Is there a role for endorectal balloons in prostate radiotherapy? A systematic review. Radiother Oncol. 2010;95(3):277-282. doi:10.1016/j.radonc.2010.04.016
  20. Both S, Deville C, Bui V, Wang KK, Vapiwala N. Emerging evidence for the role of an endorectal balloon in prostate radiation therapy. Transl Cancer Res. 2012;1(3):227-235. doi:10.3978/j.issn.2218-676X.2012.10.10
  21. Wang KK, Vapiwala N, Deville C, Plastaras JP, Scheuermann R, Lin H et al. A study to quantify the effectiveness of daily endorectal balloon for prostate intrafraction motion management. Int J Radiat Oncol Biol Phys. 2012;83(3):1055-1063. doi:10.1016/j.ijrobp.2011.07.038
  22. Smeenk RJ, Louwe RJ, Langen KM, Shah AP, Kupelian PA, van Lin EN, Kaanders JH. An endorectal balloon reduces intrafraction prostate motion during radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(2):661-669. doi:10.1016/j.ijrobp.2011.07.028
  23. Steiner E, Georg D, Goldner G, Stock M. Prostate and patient intrafraction motion: impact on treatment time-dependent planning margins for patients with endorectal balloon. Int J Radiat Oncol Biol Phys. 2013;86(4):755-761. doi:10.1016/j.ijrobp.2013.02.035
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.